Chondrosarcoma Market

• Among the 7MM countries, the total Chondrosarcoma Market Size in the United States was ~USD 8.5 million in 2023 and is aniticipated to grow with a significant CAGR during the forecast period (2024–2034).
• The total number of incident cases of chondrosarcoma in the 7MM was around 2,300 in 2023.
• Chondrosarcoma, a type of bone cancer, is categorized into four Grades: I, II, III, and IV. The majority of cases fall within Grade II.
• Leading Chondrosarcoma companies like Epizyme, Bayer, and Eli Lilly are actively advancing research and innovative therapies to address unmet needs in the treatment of this rare bone cancer.
• Chondrosarcoma primarily affects adults and is the second most common primary solid tumor of bone after osteogenic sarcoma.
• Chondrosarcoma stages range from low to high grade, indicating tumor aggressiveness. Early stages grow slowly, while advanced stages may spread to other organs, requiring more intensive treatment strategies.
• Chondrosarcoma prevalence is relatively low, primarily affecting adults over 40, with cases varying globally. Accurate diagnosis and early detection are essential for effective treatment and improved patient outcomes.
• Since there are no approved therapies, the development of molecule-targeting drugs and immunotherapy that improve clinical outcomes and reduce recurrence in patients with advanced chondrosarcoma may have beneficial and vast market opportunities in the chondrosarcoma landscape.
• Chondrosarcoma companies focus on developing treatments and therapies for this rare bone cancer. Some key companies include: Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, and others.
• Surgery remains the mainstay of treatment. Though radiotherapy and chemotherapy are also preferred in chondrosarcoma treatment, resistance to these conventional approaches leaves wide surgical resection as the only option available for both primary and secondary chondrosarcomas, highlighting a major treatment dilemma.
• Both Chemotherapy and Radiotherapy do not provide any benefit in the case of Conventional Chondrosarcoma, which is a major type of primary chondrosarcoma.
• Novel therapeutic approaches targeting IDH-mutations may sparkle in the chondrosarcoma treatment space and can grab a major share of the untapped market, as nearly 65% of chondrosarcoma cases are related to IDH-mutations.
• As per the updated NCCN guidelines ivosidenib has been added as a treatment option for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma.
• As per ESMO’s 2021 clinical practice guideline for diagnosis, treatment, and follow-up, trabectedin may be an option in mesenchymal chondrosarcoma.
• INBRX-109 is the one of lead assets in the emerging landscape and is capable of offering a newer treatment option for the unresectable conventional chondrosarcoma patient’s pool prolonging their PFS with a better safety profile.

Request for unlocking the sample page of the "Chondrosarcoma Treatment Market"

DelveInsight's “Chondrosarcoma Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chondrosarcoma Treatment Market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Chondrosarcoma market size from 2020 to 2034. The report also covers current Chondrosarcoma treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Chondrosarcoma Treatment Market: Understanding and Treatment Algorithm

Chondrosarcoma comprises a group of locally aggressive or malignant cartilaginous matrix-producing neoplasms with diverse morphological features and clinical behavior. They predominantly arise in bones derived from endochondral ossification, the most common sarcoma of bone in patients above the age of 20. It predominantly affects individuals in the fourth to sixth decades of life; the most commonly involved sites are the pelvis bones, followed by the femur, humerus, and ribs. Division of chondrosarcoma lesions by histologic grade carries the most prognostic significance.

 Chondrosarcoma Diagnosis

Chondrosarcoma diagnosis involves a thorough process beginning with a review of the patient's medical history and a physical examination to identify potential signs and symptoms. Imaging tests such as X-rays, CT scans, and MRI scans are then utilized to visualize the tumor and assess its size, location, and extent. If a tumor suspicious of chondrosarcoma is detected, a biopsy is performed to obtain a tissue sample for microscopic examination by a pathologist, confirming the diagnosis. The tumor tissue is further graded on a scale from I to IV based on its appearance under the microscope, aiding in determining its aggressiveness and prognosis. Staging tests may follow to assess the cancer's spread.

Further details related to country-based variations in diagnosis are provided in the report…

Chondrosarcoma Treatment Market

The grade of malignancy and the underlying subentity strongly determine the therapy and prognosis of chondrosarcoma. However, for all types of chondrosarcoma, the premise for curative treatment is adequate surgery. Only the wide compartmental tumor resection, according to Enneking, can control the tumor locally and systemically in a curative setting in high and intermediated-grade tumors. For low-grade chondrosarcoma, the intralesional or marginal resection can be adequate. Conventional chondrosarcomas are generally considered resistant to conventional chemotherapy and radiotherapy. Neoadjuvant or adjuvant chemotherapy may provide a survival advantage in dedifferentiated chondrosarcoma. The chemotherapy regimen is often based on a combination of doxorubicin and cisplatin or ifosfamide. Chondrosarcoma clinical trials focus on evaluating novel therapies and targeted treatments to improve outcomes in patients with this rare cancer.

Chondrosarcoma Epidemiology

The Chondrosarcoma epidemiology chapter in the Chondrosarcoma treatment market report provides historical as well as forecasted epidemiology segmented by Total Incident cases of Chondrosarcoma,  Primary Chondrosarcoma cases, Grade-specific cases of Chondrosarcoma, Mutation-specific cases of Chondrosarcoma and Stage-specific cases of Chondrosarcoma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. 

• Among the 7MM, the US accounted for the highest incident cases of chondrosarcoma in 2023. 
• In 2023, the total Incident cases of Chondrosarcoma were approximately 1,300 cases in the US, which is expected to grow during the forecast period.
• Among EU4 and the UK, France accounted for the highest number of Chondrosarcoma Incident cases, while Spain accounted for the least Incident cases.
• Among the stage-specific incident cases of chondrosarcoma, localized cases contribute the most in Japan.
• As per analysis, Conventional chondrosarcomas represent ∼80% of all chondrosarcomas.

Chondrosarcoma Drug Chapters

The drug chapter segment of the Chondrosarcoma treatment market report encloses a detailed analysis of Chondrosarcoma's emerging drugs of late-stage (Phase III and Phase II) Chondrosarcoma pipeline drugs. It also deep dives into the pivotal Chondrosarcoma clinical trials detail, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. The Chondrosarcoma drugs market is growing due to advancements in targeted therapies and increasing demand for effective treatments.

Chondrosarcoma Marketed Drugs

There is no approved drug for the Chondrosarcoma treatment. As per the updated NCCN guidelines ivosidenib has been added as a treatment option for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma, however, for all types of chondrosarcoma, the premise for curative treatment is adequate surgery. The Chondrosarcoma drugs market is witnessing growth due to rising cases, ongoing research, and emerging therapies, offering new hope for patients battling this rare bone cancer globally.

Emerging Chondrosarcoma Drugs

• INBRX-109: Inhibrx

INBRX-109 is the most advanced therapeutic candidate of Inhibrx and is designed to target tumor-biased direct cell death induction by DR5 activation in numerous cancer types. DR5 is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). DR5 activation naturally eliminates damaged and/or neoplastic cells; normal cells are less sensitive to DR5-mediated cell death. INBRX-109 is a tetravalent DR5 agonistic antibody that can potentize DR5 through efficient receptor clustering, causing cell death. Currently, the drug is being evaluated in a potentially registration-enabling Phase II trial, and the company anticipates topline data readout from this pivotal trial by the second half of 2024, which will pave the path to approval in chondrosarcoma by 2025.

• TIBSOVO (ivosidenib): Servier

TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor developed by Servier. A Phase III, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib is underway for participants aged 18 years and older with locally advanced or metastatic conventional chondrosarcoma harboring an IDH1 mutation, whether untreated or previously treated with one systemic treatment regimen. It is expected to be completed by 2031.

Note: Detailed emerging therapies assessment will be provided in the final report....

Chondrosarcoma Drugs Market Insights

Novel IDH inhibitors like AG-120 (ivosidenib) are showing potential in Phase III trials, particularly for patients with IDH1 mutations, with encouraging clinical activity observed. Additionally, targeting the Hedgehog pathway is being explored, although clinical trial results have been mixed. Inhibitors of the SRC pathway, such as dasatinib, demonstrate therapeutic benefits in preclinical studies, while inhibition of the PI3K-Akt-mTOR pathway shows promise in suppressing tumor progression. Histone deacetylase inhibitors and angiogenesis inhibitors also offer potential avenues for treatment, with ongoing research focusing on their efficacy in chondrosarcoma. These insights provide valuable directions for developing targeted therapies and combination approaches to improve outcomes for patients with chondrosarcoma.

Chondrosarcoma Market Outlook

The current management of chondrosarcoma depends on the type, the grade, and the location of the tumor, while the best predictor of clinical behavior is the grading system from I to III. It is well-established that surgical treatment is the best and the only treatment for chondrosarcoma, as other treatments, such as radiotherapy and chemotherapy, are rendered unresponsive and refractory. Curettage, radical resection, and amputation are the primary surgical treatment options, while these procedures often require considerable judgment and are based on factors such as the size and site of the lesion and its degree of malignancy. 

However, a major roadblock while estimating the revenue generated by systemic agents in chondrosarcoma is chemotherapy, which is generally ineffective in conventional chondrosarcoma, and there is no standard systemic therapy for advanced conventional chondrosarcoma either, unlike other solid tumors. The major reasons for chemoresistance, which various experts have proposed, are slow proliferation rate, expression of multidrug-resistance 1 gene P-glycoprotein resulting in resistance to doxorubicin in vitro, increased activity of antiapoptotic and prosurvival pathways as suggested by high expression of BCL-2 family proteins, and large areas of extracellular matrix accompanied by poor vascularity resulting in reduced access of the antineoplastic agents. The rarity of these cancers makes randomized clinical trials to evaluate the efficacy of systemic therapy more challenging. Current chemotherapy recommendations include cisplatin and doxorubicin, extrapolated from recommended osteosarcoma and Ewing sarcoma treatment regimens. Other combinations of Gemcitabine, Ifosfamide, Dasatinib, and Pazopanib have also been used but with limited success, especially in dedifferentiated and metastatic cases.

Key Chondrosarcoma Companies like Inhibrx, Servier, and others are evaluating their lead candidates in different stages of clinical development.

• The total Chondrosarcoma Market Size in the United States was approximately USD 8.5 million in 2023 and is projected to increase during the forecast period (2024–2034).
• Among EU4 countries, France accounted for the maximum Chondrosarcoma market size in 2023, while Spain occupied the bottom of the ladder.
• In 2023, among the first-line therapies for chondrosarcoma, the highest revenue was generated by Ivosidenib followed by chemotherapy in the United States.

Chondrosarcoma Drugs Uptake

This section focuses on the uptake rate of potential Chondrosarcoma drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Ongoing clinical trials are evaluating the clinical activity of novel IDH inhibitors. AG-120 or ivosidenib, an oral IDH2 inhibitor, is currently being tested in a Phase III trial to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation. The IDH inhibitors AG-881 and AG-120 are also under clinical evaluation in Phase I studies of advanced solid tumors that harbor an IDH1 and/or IDH2 mutation, including gliomas, cholangiocarcinomas, and chondrosarcomas. Moreover, an ongoing Phase Ib, open-label, single-center, nonrandomized clinical trial evaluates the toxicity and efficacy of metformin in combination with chloroquine in IDH1/2 mutated patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma.

Chondrosarcoma Activities

The Chondrosarcoma pipeline report provides insights into Chondrosarcoma clinical trials within Phase III and II. It also analyzes key Chondrosarcoma Companies involved in developing targeted therapeutics. 

Chondrosarcoma Pipeline Development Activities

The Chondrosarcoma clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Chondrosarcoma emerging therapies. Chondrosarcoma Companies like Inhibrx and Servier are actively engaged in late-stage research and development efforts for chondrosarcoma. Despite the relatively limited pipeline of potential drugs for this condition, the outlook for the Chondrosarcoma therapeutics market is positive, with anticipated growth from 2024 to 2034. This optimism is fueled by ongoing advancements in understanding chondrosarcoma biology, coupled with increased investment in innovative treatment approaches.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific Writers, Professors, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 18+ KOLs in the 7MM. Centers such as Sarcoma Oncology Center, Abramson Cancer Center, UC Davis Comprehensive Cancer Center in Sacramento, etc. were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Chondrosarcoma market trends.

Chondrosarcoma Qualitative Analysis

We perform qualitative and Chondrosarcoma therapeutics market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, Chondrosarcoma competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. The analyst views analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. 

Chondrosarcoma Therapeutics Market Access and Reimbursement 

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders. The payment models are based on clinical outcomes, annuity payments, and expanded risk pools. The pharmaceutical Chondrosarcoma Companies must grant the following rebates: the general rebate of 7% of the manufacturer’s price will be paid by the pharmaceutical companies to the SHIs (Statutory health insurance funds) for all pharmaceuticals that are not subject to more specific price regulations.

A special rebate of 10% of the manufacturer’s price is to be paid by the pharmaceutical companies to the SHIs for generics. Special rebates for vaccines are to be paid by the pharmaceutical companies to the SHIs and are calculated based on actual average prices in the four member states of the EU with gross national incomes. The Chondrosarcoma therapeutics market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Chondrosarcoma Therapeutics Market Report Scope

• The Chondrosarcoma drugs market report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available and emerging therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current Chondrosarcoma treatment market landscape.
• A detailed review of the Chondrosarcoma therapeutics market, historical and forecasted Chondrosarcoma market size, Chondrosarcoma market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Chondrosarcoma therapeutics market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Chondrosarcoma Drugs Market.

Chondrosarcoma Therapeutics Market Report Insights

• Patient-based Chondrosarcoma Market Forecasting
• Chondrosarcoma Therapeutic Approaches
• Chondrosarcoma Pipeline Analysis
• Chondrosarcoma Market Size and Trends
• Chondrosarcoma Drugs Market
• Existing and future Chondrosarcoma Therapeutics Market Opportunity 

Chondrosarcoma Therapeutics Market Report Key Strengths

• 11 Years Chondrosarcoma Market Forecast
• The 7MM Coverage 
• Chondrosarcoma Epidemiology Segmentation
• Key Cross Competition 
• Conjoint analysis
• Chondrosarcoma Drugs Uptake
• Key Chondrosarcoma Market Forecast Assumptions

Chondrosarcoma Treatment Market Report Assessment

• Current Chondrosarcoma Treatment Market Practices
• Chondrosarcoma Unmet Needs
• Chondrosarcoma Pipeline Product Profiles
• Chondrosarcoma Therapeutics Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Chondrosarcoma Market Drivers
• Chondrosarcoma Market Barriers

FAQs

• What is the historical and forecasted Chondrosarcoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What was the total Chondrosarcoma market size, the market size by therapies, market share (%) distribution in 2023, and what would it look like in 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved and off-label therapies?
• What are the disease risks, burdens, and Chondrosarcoma unmet needs? What will be the growth opportunities across the 7MM concerning the Chondrosarcoma patient population?
• What are the current and emerging options for treating Chondrosarcoma? 
• How many Chondrosarcoma companies are developing therapies to treat Chondrosarcoma?
• What are the recent novel therapies, targets, Chondrosarcoma mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy Chondrosarcoma Treatment Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the chondrosarcoma treatment market.
• Insights on patient burden/disease Chondrosarcoma prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Chondrosarcoma treatment market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the Chondrosarcoma treatment market will help devise strategies to help get ahead of competitors.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Chondrosarcoma treatment market so that the upcoming players can strengthen their development and launch strategy.

Stay Updated with us for Recent Articles

• Chondrosarcoma Treatment Market: Insight on Patient Burden and Inhibrx’s INBX-109 US Market Entry in 2026
• Chondrosarcoma Infographics